Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...

There’s a new kind of nosy parker in the United States, a person who seems to think it’s fine to blurt out “Are you on ...

A WOMAN who’s lost almost five stone on Mounjaro has admitted she’s willing to get herself into debt to stay on it amid the upcoming price hike. The fat jab community was left panicked ...

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

An estimated 2·1 billion adults worldwide are affected by overweight and obesity, a figure projected to reach 3·8 billion by ...

During a weeklong joint operation between U.S. Customs and Border Protection and U.S. Food and Drug Administration, CBP officers inspected hundreds of boxes containing possible counterfeit and ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Yesterday, US pharmaceutical giant Lilly announced the cost would soar from September 1, with a month's supply of the highest ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...